Cargando…
The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis
BACKGROUND: Although incretin therapy is clinically available in patients with type 2 diabetes undergoing hemodialysis, no study has yet examined whether incretin therapy is capable of maintaining glycemic control in this group of patients when switched from insulin therapy. In this study, we examin...
Autores principales: | Terawaki, Yuichi, Nomiyama, Takashi, Akehi, Yuko, Takenoshita, Hiromasa, Nagaishi, Ryoko, Tsutsumi, Yoko, Murase, Kunitaka, Nagasako, Hisahiro, Hamanoue, Nobuya, Sugimoto, Kaoru, Takada, Ayako, Ito, Kenji, Abe, Yasuhiro, Sasatomi, Yoshie, Ogahara, Satoru, Nakashima, Hitoshi, Saito, Takao, Yanase, Toshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598214/ https://www.ncbi.nlm.nih.gov/pubmed/23445717 http://dx.doi.org/10.1186/1758-5996-5-10 |
Ejemplares similares
-
Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
por: Terawaki, Yuichi, et al.
Publicado: (2015) -
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
por: Terawaki, Yuichi, et al.
Publicado: (2014) -
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
por: Tsutsumi, Yoko, et al.
Publicado: (2015) -
Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database
por: Tanabe, Makito, et al.
Publicado: (2015) -
SUN-026 Selective Androgen Receptor Modulator S42 Has Anabolic and Anti-Catabolic Effects on Cultured Myotubes
por: Muta, Yoshimi, et al.
Publicado: (2019)